NASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free AYTU Stock Alerts $3.02 -0.04 (-1.31%) (As of 01:10 PM ET) Add Compare Share Share Today's Range$2.75▼$3.3550-Day Range$2.67▼$3.3652-Week Range$1.38▼$3.50Volume37,259 shsAverage Volume19,108 shsMarket Capitalization$16.82 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Aytu BioPharma alerts: Email Address Aytu BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside69.5% Upside$5.00 Price TargetShort InterestBearish7.15% of Float Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.75Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector323rd out of 929 stocksPharmaceutical Preparations Industry147th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingAytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAytu BioPharma has received no research coverage in the past 90 days.Read more about Aytu BioPharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.15% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 18.5, which indicates bearish sentiment.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 4.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAytu BioPharma has received a 39.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Carbinoxamine", "Methylphenidate", and "Amphetamine" products. See details.Environmental SustainabilityThe Environmental Impact score for Aytu BioPharma is -2.45. Previous Next 2.6 News and Social Media Coverage News SentimentAytu BioPharma has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aytu BioPharma this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.34% of the stock of Aytu BioPharma is held by insiders.Percentage Held by InstitutionsOnly 33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aytu BioPharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aytu BioPharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThis is the best new way to score with AIIf you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects About Aytu BioPharma Stock (NASDAQ:AYTU)Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.Read More AYTU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AYTU Stock News HeadlinesMay 16 at 1:01 PM | finance.yahoo.comQ3 2024 Aytu Biopharma Inc Earnings CallMay 16 at 8:00 AM | finance.yahoo.comAytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ...May 15 at 4:58 PM | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial ResultsMay 15 at 4:58 PM | markets.businessinsider.comHere's what Wall Street expects from Aytu BioPharma's earnings reportApril 17, 2024 | morningstar.comAytu BioPharma Inc 0A8MApril 2, 2024 | msn.comRedHill Biopharma looks to raise $1.25M in a direct offering of securitiesMarch 24, 2024 | morningstar.comAytu BioPharma Inc AYTUMarch 19, 2024 | seekingalpha.comSeelos drops as lead drug fails in ALS trialMarch 18, 2024 | seekingalpha.comSeelos Therapeutics files for 3.4M shares secondary offeringFebruary 25, 2024 | msn.comAytu BioPharma (AYTU) Price Target Increased by 60.00% to 8.16February 16, 2024 | finance.yahoo.comAytu BioPharma Second Quarter 2024 Earnings: Beats ExpectationsFebruary 16, 2024 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comQ2 2024 Aytu Biopharma Inc Earnings CallFebruary 14, 2024 | finance.yahoo.comAytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterFebruary 13, 2024 | benzinga.comEarnings Preview: Aytu BioPharmaFebruary 7, 2024 | finance.yahoo.comAytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024January 23, 2024 | finance.yahoo.comAytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 16, 2024 | finance.yahoo.comWhen Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?December 18, 2023 | benzinga.comAytu BioPharma Stock (NASDAQ:AYTU) Dividends: History, Yield and DatesNovember 30, 2023 | finance.yahoo.comAytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023November 15, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call TranscriptNovember 14, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 14, 2023 | finance.yahoo.comAytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 13, 2023 | markets.businessinsider.comAytu BioPharma earnings: here's what to expectNovember 8, 2023 | finance.yahoo.comAytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive YearSee More Headlines Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/16/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AYTU CUSIPN/A CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+69.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,050,000.00 Net Margins-18.27% Pretax Margin-17.43% Return on Equity-41.00% Return on Assets-10.87% Debt Debt-to-Equity Ratio0.46 Current Ratio1.11 Quick Ratio0.91 Sales & Book Value Annual Sales$107.40 million Price / Sales0.15 Cash Flow$0.87 per share Price / Cash Flow3.39 Book Value$10.41 per share Price / Book0.28Miscellaneous Outstanding Shares5,570,000Free Float5,326,000Market Cap$16.43 million OptionableNot Optionable Beta-1.23 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Joshua R. Disbrow (Age 49)Chairman & CEO Comp: $708kMr. Mark K. Oki CPA (Age 55)CFO, Secretary & Treasurer Comp: $522.84kMr. Greg Pyszczymuka (Age 45)Chief Commercial Officer Comp: $525kMs. Victoria CordovaVice President of People & CultureMr. Jarrett T. Disbrow Ph.D. (Age 49)Chief Business Officer & President of Consumer Health Comp: $355kMr. Russ McMahenSenior Vice President of Research & DevelopmentMr. Ryan J. Selhorn CPA (Age 42)Executive VP of Finance & Business Optimization More ExecutivesKey CompetitorsGalectoNASDAQ:GLTOSol-Gel TechnologiesNASDAQ:SLGLIndaptus TherapeuticsNASDAQ:INDPVBI VaccinesNASDAQ:VBIVCocrystal PharmaNASDAQ:COCPView All CompetitorsInsidersGreg PyszczymukaBought 12,000 shares on 6/16/2023Total: $22,440.00 ($1.87/share)Joshua R DisbrowBought 14,000 shares on 6/14/2023Total: $26,040.00 ($1.86/share)View All Insider Transactions AYTU Stock Analysis - Frequently Asked Questions Should I buy or sell Aytu BioPharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AYTU shares. View AYTU analyst ratings or view top-rated stocks. What is Aytu BioPharma's stock price target for 2024? 1 analysts have issued 1-year target prices for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts. How have AYTU shares performed in 2024? Aytu BioPharma's stock was trading at $2.84 at the beginning of 2024. Since then, AYTU shares have increased by 3.9% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma, Inc. (NASDAQ:AYTU) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.60. The business had revenue of $21.90 million for the quarter. Aytu BioPharma had a negative net margin of 18.27% and a negative trailing twelve-month return on equity of 41.00%. During the same period in the prior year, the company posted ($0.40) earnings per share. When did Aytu BioPharma's stock split? Aytu BioPharma shares reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX). Who are Aytu BioPharma's major shareholders? Aytu BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Greg Pyszczymuka and Joshua R Disbrow. View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AYTU) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.